STENTYS 2012 Annual Revenues up 77% over Prior Year

  STENTYS 2012 Annual Revenues up 77% over Prior Year

  * Strong continued revenue growth
  * 2013 : acceleration in scientific and marketing developments
  * Cash position of €45.6 million at 31 December 2012
  * STENTYS now listed on compartment B of NYSE Euronext

Business Wire

PRINCETON, N.J. & PARIS -- January 24, 2013

STENTYS (FR0010949404 – STNT), a medical technology company commercializing in
Europe the world's first and only Self-Apposing^® stent to treat acute
myocardial infarction (AMI), today reports its fourth quarter and full year
revenues^1 for the year 2012.

  * 2012 fourth quarter and annual revenues

                                                                            
                        Annual – 12 months                                 Quarterly – 3 months
In €                    2012            2011            Var                Q4            Q4            Var
thousands                                               %                  2012          2011          %
Revenues                2,530.7         1,432.0         +77%               707.5         463.0         +53%
                                                                                                      

Over 2012 as a whole, STENTYS revenues were up 77.0% at €2,530.7 thousand.
Sales continued to grow (53%) in the fourth quarter of 2012 for a total of
€707.5 thousand, characterized by increased pressure on hospital budgets at
the year end. The sales performance recorded in 2012 continues to indicate
substantial appeal for the STENTYS Self-Apposing stent amongst cardiologists
in countries where it has been pre-marketed.

  * 2013: expanding globally

    STENTYS anticipates that 2013 will be a fruitful year in terms of
    scientific and sales development, with substantial news flow.

       * Clinical trials in Europe and the United States

         The final results of the APPOSITION III clinical trial on 1,000
         patients, one year after heart attack treatment with a STENTYS stent,
         will be presented in March at the American College of Cardiology
         conference in San Francisco (ACC.13). The results of the APPOSITION
         IV clinical trial, which compares the new STENTYS Sirolimus-eluting
         stent to Medtronic’s DES in 150 patients, are also expected to be
         presented this year at a major medical conference.

         Lastly, the Company is actively preparing the start of the pivotal
         clinical trial in the United States (APPOSITION V), with the first
         patients scheduled to be enrolled during the first half of the year.
         This first trial in the US will considerably expand the Company’s
         visibility in the world’s largest market.
       * Sales expansion beyond Europe

         Based on the experience acquired during pre-marketing activities
         underway in a number of European countries, STENTYS will enlarge its
         sales network to new geographical regions where the European CE Mark
         is recognized by working with local distributors. Furthermore, the
         Company will continue to develop its own sales force in the European
         countries where it is already present in order to improve its
         geographical coverage and increase the number of hospitals in which
         its products are available.

  * Solid cash position at end-2012

    At 31 December 2012, STENTYS had cash of €45.6 million. The strong cash
    position is due in part to €36 million in gross proceeds from the capital
    increase with rights issue successfully carried out in the fourth quarter
    of 2012.

  * STENTYS shares transferred from compartment C to compartment B of NYSE
    Euronext

    Since 17 January 2013, STENTYS shares have been transferred to compartment
    B of NYSE Euronext, which includes companies with a market cap of between
    €150 million and €1 billion. This transfer is a result of the Company’s
    capitalization at 31 December 2012 and its average capitalization over the
    last 60 trading days of the year. Such a transfer can be beneficial in
    enhancing the liquidity of STENTYS shares.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, stated:
“In 2013, STENTYS is entering a new era: the initiation of our FDA-approved US
pivotal clinical trial as well as new financial resources enable us to execute
our global strategy. We hope to confirm the excellent results of the
APPOSITION III clinical trial seen to date when we report further data in
March, and we will move on to the next stage of our sales strategy by
establishing distribution contracts in many new parts of the world.”

  * Upcoming Financial Results

    STENTYS expects to publish its 2012 annual financial results on 28 March
    2013, before market.

About STENTYS:

STENTYS is developing and commercializing innovative solutions for the
treatment of patients with acute myocardial infarction (AMI, or heart attack)
and complex coronary artery disease. STENTYS’s Self-Apposing^® Stents are
designed to adapt to vessels with ambiguous or fluctuating diameters,
particularly in the post-infarction phase, in order to prevent the
malapposition problems associated with conventional stents. In the APPOSITION
III clinical trial, STENTYS stents demonstrated a very low 30-day mortality
rate among 1,000 high-risk AMI patients when compared to recent studies with
conventional stents. More information is available at www.stentys.com. This
press release contains forward looking statements about the Company’s
business. Such forward looking statements are based on numerous assumptions
regarding the Company’s present and future business strategies and the
environment in which it will operate in the future which may not be accurate.
Such forward-looking statements involve known and unknown risks which may
cause the Company’s actual results, performance or achievements to differ
materially from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, among
others, risks associated with the development and commercialization of the
Company’s products, market acceptance of the Company’s products, its ability
to manage growth, the competitive environment in relation to its business area
and markets, its ability to enforce and protect its patents and proprietary
rights, uncertainties related to the U.S. FDA approval process, including with
respect to a pre-market approval for the Company’s BMS, slower than expected
rates of patient recruitment for clinical trials, the outcome of clinical
trials, and other factors, including those described in the Section 4 “Risk
Factors” of the Company’s 2011 Registration Document (document de référence)
filed with the Autorité des marchés financiers in France on June 25, 2012
under number R.12-033 as such section may be updated from time to time.

     STENTYS is listed on Compartment B of the NYSE Euronext Paris ISIN:
                         FR0010949404 – Ticker: STNT

^1 Unaudited

Contact:

STENTYS
Stanislas Piot, CFO, +33 (0)1 44 53 99 42
stan.p@stentys.com
or
Europe: NewCap.
Axelle Vuillermet / Pierre Laurent, +33 (0)1 44 71 94 93
stentys@newcap.fr
or
US: MacDougall Biomedical Communications
Kari Watson, +1-781-235-3060
or
Christine Labaree, +1-650-339-7533
stentys@macbiocom.com